Chapter 1
Introduction: Drug Discovery in Difficult Times
Malcolm Maccoss,
Malcolm Maccoss
Bohicket Pharma Consulting LLC, South Carolina, USA
Search for more papers by this authorMalcolm Maccoss,
Malcolm Maccoss
Bohicket Pharma Consulting LLC, South Carolina, USA
Search for more papers by this authorBook Editor(s):Xianhai Huang, Robert G. Aslanian,
First published: 11 May 2012
REFERENCES
- Price water house Coopers., Pharma 2020: The Vision, 2007.
- International Human Genome Sequencing, Consortium. Initial sequencing and analysis of the human genome. Nature 2001, 409, 860–921.
- VENTER J. C. et al. The sequence of the human genome. Science 2001, 291, 1304–1351.
- MUNOS, B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 2009, 8, 959–968.
- PAUL S. M., MYTELKA D. S., DUNWIDDIE C. T., PERSINGER C. C., MUNOS B. H., LINDBORG S.R., and SCHACHT A. L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9, 203–214.
- KOLA I. and LANDIS, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004, 3, 711–715.
- SCHUSTER, D., LAGGNER, C., and LANGER, T. Why drugs fail: a study on side effects in new chemical entities. Curr. Pharm. Des. 2005, 11, 3545–3559.
- GARNIER, J.-P. Rebuilding the R&D engine in big pharma. Harv. Bus. Rev. 2008, 8, 68–70.
- Accenture. Achieving high performance in pharmaceuticals through sustainable cost reduction, 2009.
- SPECTOR, R. A Skeptic's view of pharmaceutical progress. CSI Skeptical Inquirer July/August, 2010, 34(4). http://www.csicop.org/si/show/a_skepties_view_of_pharmaceutical_progress
- DOUGLAS, F. L., NARAYANAN, V. K., MITCHELL L., and LITAN, R. E. The case for entrepreneurship in R&D in the pharmaceutical industry. Nat. Rev. Drug Discov. 2010, 9, 683–689.
- SLATER, E. E. and KAITIN, K. Pharmaceutical Executive, September 2010, p. 22.
- TEAGUE, S. J. Learning lessons from drugs that have recently entered the market. Drug Discov. Today 2011, 16, 398–411.
- CUATRECASAS, P. Interview with Pedro Cuatrecasas. Nat. Rev. Drug Discov. 2009, 8, 446.
- CUATRECASAS, P. Drug discovery in jeopardy? J. Clin. Invest. 2006, 116, 2837–2842.
- HERPER, M. 2011, http://blogs.forbes.com/matthewherper/2011/04/13/a-decade-in-drug-industry-layoffs/#comment-2923.
- MERCK, G. W. (December 1950), in a speech at the Medical College of Virginia.
- GRABOWSKI, H. G. and KYLE, M. In The Economics of Corporate Governance and Mergers (eds K. Gugler and B. Yurtoglu), Edward Elgar, Cheltenham, 2008, p. 262.
- ULLMAN, F. and BOUTELLIER, R. A case study of lean drug discovery: from project driven research to innovation studios and process factories. Drug Discov. Today 2008, 13, 543–550.
- Paracelsus (1493–1541), “All things are poison, and nothing is without poison; only the dose permits something not to be poisonous.”
- BOOTH, B., GLASSMAN, R., and MA, P. Oncology's trials. Nat. Rev. Drug Discov. 2003, 2, 609–610.
- LIPINSKY, C. A., LOMBARDO, F., DOMINY; B. W., and FEENEY, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3–26.
- MACCOSS, M. and BAILLIE, T. A. Organic chemistry in drug discovery. Science 2004, 303, 1810–1813.
- ROUGHLEY, S. D. and JORDAN, A.M. The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 2011, 54, 3451–3479.
- LOWE, D. 2011, http://pipeline.corante.com/archives/2011/05/09/what_medicinal_chemists_really_make. php.
- BROOKS, W. H., GUIDA, W. C., and DANIEL, K. G. The significance of chirality in drug design and development. Curr. Top. Med. Chem. 2011, 11, 760–770.
- LOVERING, F., BIKKER, J., and HUMBLET, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 2009, 52, 6752–6756.
- KINGWELL, K. Medicinal chemistry: exploring the third dimension. Nat. Rev. Drug Discov. 2009, 8, 931.
